What a Trump Bid for Cut of Chip Revenue Means for China
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
Multiple Myeloma Market Trends and Company Analysis Report 2025-2033 Featuring BMS, Novartis, Abbvie, Sanofi, Johnson and Johnson, Baxter, Pfizer, and Takeda
The Global Multiple Myeloma Market is projected to grow from USD 21.78 billion in 2024 to USD 40.41 billion by 2033, at a CAGR of 7.11%. Growth drivers include rising multiple myeloma cases, advances in targeted therapies like monoclonal antibodies, and the increasing adoption of immunotherapies. Enhanced diagnostics and greater healthcare accessibility are boosting market expansion. Key regions such as the U.S., Europe, and Asia-Pacific, are witnessing heightened therapy adoption. Challenges include high therapy costs and resistance to current treatments. Major players investing in R&D include Novartis, Abbvie, and Bristol-Myers Squibb. Key terms: Global Multiple Myeloma Market, Multiple Myeloma Growth, Targeted Therapies, Immunotherapies, Market Expansion. Multiple Myeloma Market Dublin, Aug. 12, 2025 (GLOBE NEWSWIRE) -- The "Multiple Myeloma Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" report has been added to Global Multiple Myeloma Market was valued at USD 21.78 billion in 2024 and is expected to reach USD 40.41 billion by the year 2033, at a CAGR of 7.11% during the forecast period from 2025 to 2033 The growth of the market is fueled by the increasing number of multiple myeloma cases, developments in targeted therapies, and the expanding use of immunotherapies. Increased oncology research, enhanced diagnostic methodologies, and the increasing availability of healthcare facilities are further adding to market growth. The therapies for multiple myeloma are chemotherapy, immunotherapy, target therapies, corticosteroids, and stem cell transplants. Increasing advancements in monoclonal antibodies and CAR-T cell therapy are enhancing outcomes among patients, and these therapies are becoming more popular globally. With increasing awareness of cancer and better diagnosis methods, multiple myeloma therapies are becoming increasingly popular in the U.S., Europe, and Asia-Pacific. Pharmaceutical industries are heavily investing in new drug development, and governments are also funding cancer research, further propelling treatment availability. Consequently, the multiple myeloma market continues to grow, bringing new hope to patients of Growth in the Multiple Myeloma Market Improvements in Targeted TherapiesThe emergence of targeted therapies like monoclonal antibodies and proteasome inhibitors has considerably enhanced treatment efficacy for multiple myeloma patients. These treatments have greater efficacy with less side effect than conventional chemotherapy. With continued research in immunotherapy and CAR-T cell therapy, more effective therapies are being made available, and patient survival is on the rise. Consequently, drug companies are investing heavily in drug development, further fueling market growth. Dec 2024, Merck reported that the FDA has accepted for filing the Biologics License Application for clesrovimab (MK-1654), a long-acting monoclonal antibody to help protect infants from RSV in their first RSV Prevalence of Multiple MyelomaThe worldwide prevalence of multiple myeloma is on the rise, especially among the elderly. Genetic susceptibility, exposure to toxic chemicals, and lifestyle changes are factors that lead to an increased incidence of the disease. As more and more cases are being diagnosed yearly, the need for effective treatment options is on the rise. This has driven governments and health organizations to invest more in multiple myeloma research and the availability of treatments, driving market growth. There were about 35,000 cases of MM in 2021 globally, with the most in China and Germany, with 47,003 and 32,010 cases, respectively. In 2021, Europe boasted the highest ASIR and ASPR, and North America the highest ASMR and Healthcare Spending and AwarenessRising healthcare spending in developed and emerging economies is contributing positively towards the multiple myeloma market. Governments and private bodies are initiating awareness campaigns and screening programs to encourage early detection and timely treatment. Patients now enjoy improved access to new therapies through reimbursement schemes and insurance coverage, also driving the adoption of treatments. With increasing numbers of hospitals and clinics incorporating advanced oncology treatments, the multiple myeloma market is set to see significant in the Multiple Myeloma Market Exorbitant Cost of TherapyImmunotherapies and targeted agents used in treating multiple myeloma are costly, hence unavailable to most patients, particularly those in developing areas. Bone marrow transplants and maintenance therapy costs further increase the burden. In spite of availability of reimbursement schemes in certain countries, affordability becomes a serious concern, limiting the growth of the Effects and Therapy ResistanceIn spite of the progress in treatment, patients tend to develop resistance to current therapies with time, which requires frequent modification of treatment regimens. Moreover, most therapies have serious side effects, such as infections, tiredness, and organ injury, which lower the quality of life for patients. These issues propel the necessity for ongoing research and innovation in treatment methods. Key Players Analyzed: Overview, Key Persons, Recent Developments, Product Portfolio, Revenue Novartis AG Abbvie Inc. Sanofi Johnson and Johnson Baxter International Inc. Pfizer Inc. Takeda Pharmaceutical Company Ltd Bristol-Myers Squibb Company Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $21.78 Billion Forecasted Market Value (USD) by 2033 $40.41 Billion Compound Annual Growth Rate 7.1% Regions Covered Global Key Topics Covered: 1. Introduction2. Research & Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Global Multiple Myeloma Market6. Market Share Analysis6.1 By Drugs Types6.2 By Disease Types6.3 By End User6.4 By Country7. Drugs Types7.1 Chemotherapy7.2 Protease Inhibitors7.3 Monoclonal Antibody7.4 Others8. Disease Types8.1 Active multiple myeloma8.2 Smoldering multiple myeloma9. End User9.1 Hospitals9.2 Clinics9.3 Others10. Countries10.1 North America10.1.1 United States10.1.2 Canada10.2 Europe10.2.1 France10.2.2 Germany10.2.3 Italy10.2.4 Spain10.2.5 United Kingdom10.2.6 Belgium10.2.7 Netherlands10.2.8 Turkey10.3 Asia-Pacific10.3.1 China10.3.2 Japan10.3.3 India10.3.4 Australia10.3.5 South Korea10.3.6 Thailand10.3.7 Malaysia10.3.8 Indonesia10.3.9 New Zealand10.4 Latin America10.4.1 Brazil10.4.2 Mexico10.4.3 Argentina10.5 Middle East & Africa10.5.1 South Africa10.5.2 Saudi Arabia10.5.3 United Arab Emirates11. Porter's Five Forces Analysis11.1 Bargaining Power of Buyers11.2 Bargaining Power of Suppliers11.3 Degree of Competition11.4 Threat of New Entrants11.5 Threat of Substitutes12. SWOT Analysis12.1 Strength12.2 Weakness12.3 Opportunity12.4 Threats13. Key Players Analysis For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Multiple Myeloma Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15 minutes ago
- Yahoo
Sea Limited shares jump as revenue surges 38% in second quarter
-- Sea Limited shares surged 9.4% premarket on Tuesday after the Southeast Asian tech firm reported second-quarter revenue that significantly exceeded analyst expectations, despite an earnings miss. The company posted revenue of $5.3 billion for the quarter ended June 30, 2025, soaring 38.2% year-over-year and handily beating the consensus estimate of $4.55 billion. However, adjusted earnings per share came in at $0.65, falling short of analysts' expectations of $0.77. Net income reached $414.2 million, a dramatic improvement from $79.9 million in the same period last year. Sea's e-commerce platform Shopee continued its strong performance with gross merchandise value (GMV) increasing 28.2% year-over-year to $29.8 billion, while gross orders grew 28.6% to 3.3 billion. The digital financial services segment saw revenue jump 70% to $882.8 million, while digital entertainment bookings rose 23.2% to $661.3 million. "All three of our businesses have delivered robust, healthy growth, giving us greater confidence of delivering another great year," said Forrest Li, Sea's Chairman and Chief Executive Officer. "Given the high potential of our markets and the stage we are at in our business now, we will continue to prioritize growth, which will pave the way for us to maximize our long-term profitability." The company's digital financial services arm reported consumer and SME loans principal outstanding of $6.9 billion, up 94% YoY, while maintaining a low non-performing loan ratio of 1.0%. Meanwhile, the digital entertainment segment saw quarterly active users increase 2.6% to 664.8 million, with paying users rising 17.8% to 61.8 million. Total adjusted EBITDA reached $829.2 million, representing an 84.9% increase from $448.5 million in the second quarter of 2024. The e-commerce segment achieved a significant turnaround, generating adjusted EBITDA of $227.7 million compared to a loss of $9.2 million in the same period last year. Related articles Sea Limited shares jump as revenue surges 38% in second quarter Victoria's Secret Exposed: The Warning Sign Behind the Stock's 52% Collapse 7 Undervalued Stocks on the Rise With 50%+ Upside Potential Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15 minutes ago
- Yahoo
OPINION - This is why we should scrap the tourist tax
Walk down any of London's shopping streets today and you'll notice something missing – not the designer shops or beautiful window displays, but the international tourists. The visitors who once spent freely in our stores, stayed in our hotels, dined in our restaurants and enriched the whole economy are no longer coming to our great city in the numbers we used to see. Many now bypass London entirely for Paris, Milan or Madrid. Those that do come are spending less than they used to. Why? Because the UK scrapped tax-free shopping. This decision by the last government was one of the most self-defeating in recent memory. Since the abolition of VAT-free purchases for tourists in 2021, the UK has become the only major country in Europe which doesn't offer VAT refunds to international visitors. And let me tell you the consequences are stark. One is that fewer people are coming to our shores. New figures show that while visitor numbers in the UK have almost returned to pre-pandemic levels, we haven't seen anything like the growth that our EU rivals have. And according to new figures from the Association of International Retail (AIR), tourist spending is eight per cent down on 2019. Meanwhile, in France and Spain, spending has surged ahead — up ten per cent and six per cent respectively. The difference? They still offer VAT-free shopping. Yet since 2021, we don't. Despite the clear consequences. To be clear, this isn't just about a few luxury retailers in the West End. It's about the entire visitor economy, across the entire UK. Shopping accounts for a quarter of all spending by international tourists. For every pound spent in VAT-free retail, visitors spend another £4 across hospitality, transport, culture and services. That's money into the tills of restaurants in Edinburgh, taxi firms in Manchester, theatres in London and family-run hotels in the Lake District. After the decision to scrap the scheme, the excess paid by foreign visitors on their shopping was branded a 'tourist tax' – and rightly so. It has driven away high-value visitors and handed our European rivals a competitive advantage. Increasingly, British tourists are now doing their shopping on the continent, claiming VAT back in Milan while leaving British shops behind. Visitors from the US, China, the Middle East and now – post-Brexit – the EU's 450 million citizens, are being actively incentivised to go anywhere but here. Of course we see the impact across our hotel group, where tourists who once returned laden with parcels now cut UK trips short in order to add a stop in Europe where they do their shopping, knowing they can reclaim sales tax. This is madness – but it's reversible. The UK now has the chance to be the only country in Europe offering tax-free shopping to EU residents. That is a Brexit benefit hiding in plain sight. If we reintroduce a modern, digital tax-free shopping scheme, we can turn this lost opportunity into a £3.7 billion-a-year boost for Britain. A new submission to ministers by AIR puts the case clearly. Reinstating VAT-free shopping could create at least 73,000 jobs, mostly outside London, where half of EU tourist spending takes place. Regional airports, local high streets and national visitor attractions would all benefit. This policy has the backing of a united business voice. Heathrow, John Lewis, Primark, Mulberry, Bicester Village, the British Retail Consortium, the British Fashion Council, Historic Royal Palaces, Shakespeare's Globe and dozens more are calling for it. VAT-free shopping isn't a tax loss, it's a revenue driver This wouldn't cost the UK any money at a time of stretched public finances. The evidence is clear: VAT-free shopping isn't a tax loss, it's a revenue driver. The tax you give back on retail is repaid many times over in spending on goods and services where VAT still applies. Even when rebates exist, many low-value claims aren't pursued, meaning the Exchequer still keeps much of the VAT while benefiting from broader economic activity. This isn't just a London issue. Many of our overseas visitors come to see family, tour our regions or explore smaller cities. A thriving visitor economy supports restaurants in Glasgow, boutiques in Bath and hotels in Newcastle just as much as it supports central London. Britain now has a unique opportunity to become the global capital for shopping – a status we once held with pride. Now, with Britain outside the EU, we can become the only country in Europe offering tax-free shopping to EU tourists. The government talks about making Brexit work. Here is a chance to do exactly that. It's a simple change that requires only a willingness to admit that a mistake was made and to put it right. The Department for Culture, Media and Sport is currently preparing a new Visitor Economy Growth Plan. If ministers are serious about boosting tourism, supporting jobs and reviving our high streets, then reintroducing tax-free shopping should be at the top of that plan. It is not often that a government is presented with an economic lever that can deliver billions of pounds in new spending, tens of thousands of new jobs and stronger regional growth, all without raising taxes or requiring long-term subsidies. Yet that is exactly the opportunity sitting in front of ministers now with the proposal to reintroduce tax-free shopping for international visitors. It would deliver rapid, measurable gains for the UK. It is fiscally sound, economically stimulative, regionally inclusive and politically feasible. In short: it's a no-brainer. Now is the time for action. Let's stop pushing tourists into the arms of our rivals and start attracting them back to Britain. Let's scrap the tourist tax, reinstate VAT-free shopping, and make the UK the world's greatest shopping destination once again. Sir Rocco Forte is Chair of Rocco Forte Hotels
